Mr. Chair, I think most would agree that the progress Health Canada is making on improving the performance times in reviewing new drugs is laudatory. However, as the minister himself has pointed out, this is only one part of a safe pharmaceutical strategy.
As the minister knows, the Standing Committee on Health completed a report on prescription drugs. It recommended, for one thing, a public database to provide information on clinical trials in progress, trials abandoned and trials completed. We wanted to know about trials abandoned because that would give us an indication of which new drugs were having negative effects, so much so that the company cancels the trials.
Is Health Canada moving to set up a public database or registry of clinical trials which include these components of in progress, abandoned, and completed?